Regulations.gov document
Patient-Focused Drug Development for Long COVID; Public Meeting; Request for Comments
Notice · FDA-2023-N-0363 · posted Feb 23, 2023
Key facts
| Document ID | FDA-2023-N-0363-0001 |
|---|---|
| Title | Patient-Focused Drug Development for Long COVID; Public Meeting; Request for Comments |
| Document type | Notice |
| Subtype | Request for Comments |
| Agency | FDA |
| Docket | FDA-2023-N-0363 |
| Posted | Feb 23, 2023 |
| Federal Register citation | 88 FR 11447 |
| FR document number | 2023-03714 |
| Comment period opens | Feb 23, 2023 |
| Comments due | Jun 27, 2023 |
| Effective date | Feb 23, 2023 |
At a glance
- 1–9 Pages
- No Open for comment
- 100–999 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: